Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 5/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | TERT | O14746 | 2/20 | 0.59 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.59 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.59 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.59 |
| ▸ | DTYMK | P23919 | 4/20 | 0.58 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.51 |
| ▸ | TK1 | P04183 | 2/20 | 0.49 |
| ▸ | TYMS | P04818 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29415903 | 1.00 | F2 (0.68) | F2POLBTERTP2RY2P2RY4 | |
| SCHEMBL29350192 | 1.00 | F2 (0.68) | F2POLBTERTP2RY2P2RY4 | |
| SCHEMBL29671382 | 1.00 | F2 (0.68) | F2POLBTERTP2RY2P2RY4 | |
| SCHEMBL29775052 | 1.00 | F2 (0.68) | F2POLBTERTP2RY2P2RY4 | |
| SCHEMBL15672415 | 0.97 | F2 (0.65) | F2POLBTERTP2RY2P2RY4 | |
| SCHEMBL29534179 | 0.96 | F2 (0.63) | F2POLBTERTP2RY2P2RY4 | |
| SCHEMBL29533485 | 0.96 | F2 (0.63) | F2POLBTERTP2RY2P2RY4 | |
| SCHEMBL29408579 | 0.95 | F2 (0.62) | F2POLBTERTP2RY2P2RY4 | |
| SCHEMBL23009655 | 0.95 | DTYMK (0.67) | F2POLBTERTP2RY2P2RY4 | |
| SCHEMBL30103510 | 0.95 | DTYMK (0.67) | F2POLBTERTP2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606830-B2 | Protected antibody-drug and aptamer-drug conjugates | KOSAK KENNETH MICHAEL (US) | 2026-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606830-B2 | Protected antibody-drug and aptamer-drug conjugates | PABPC1, PABPC4, ABCG2 | F2 4831/4885POLB 636/4885TERT 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.